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Background
Niemann-Pick type C (NPC) is a rare, autosomal recessive
neurodegenerative lysosomal storage disorder (LSD)
caused due to mutation in either npc1 or npc2 genes.
However, 95% of the reported cases are caused due to
mutation in npc1 gene and only 5% due to the mutation in
npc2 gene. Mutations in either of these two genes results
in similar phenotype such that there is an abnormal accu-
mulation of unesterified cholesterol and glycosphingolipids
in late endosomes/ lysosomes (LE/Ly) of many cell types.
NPC1 is a multi-spanning transmembrane protein loca-
lized in limiting membrane of LE/Ly whereas NPC2 is
soluble cholesterol binding protein localized in the lumen
of LE/Ly. There are no therapeutic options to treat the
disease and the children born with this defect die before
the age of 20 years. Miglustat, a drug used to treat
Gaucher disease has been reported to stabilize NPC
patients and has also been approved for treating NPC
patients in Europe. Infusion of very high dose of chemical
chaperone like 2-hydroxypropyl-b-cyclodextrin (HPBCD)
several times a week has also been shown to reduce the
cholesterol load in peripheral tissues. Unfortunately, the
blood brain barrier (BBB) cross over capability of HPCD is
very poor and hence requires intrathecal CNS injections.
Results
We have found that the treatment of several histone
deacetylase inhibitors (HDACi), corrects the NPC defect
specifically in human patient derived NPC1, but not in
NPC2 fibroblast. Amongst the HDACi tested Vorinostat
is a FDA approved drug that has been shown to cross BBB
and is currently used in clinic for treatment of cutaneous
T-cell lymphoma and many other type of cancer. Our
initial study was conducted on most common mutation
“I1061T” found in human patients but since then we have
tested the effect of Vorinostat and other HDACi’s on
several different patient derived mutant fibroblasts.
Conclusions
Our data indicate that Vorinostat is effective in rescuing
the phenotype in most cases but to a varying degree.
This is a promising breakthrough example of repurposing
existing FDA approved drug for the treatment of NPC1
and other LSDs.
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